Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat Plus Belinostat in Relapsed or Refractory Lymphoma
NCT05627245Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat and belinostat in lymphoma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Mar 2023; status: active, not recruiting.
02
Drugs
tazemetostatbelinostat
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05627245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627245.